TL;DR: Weight loss with GLP-1 or GIP/GLP-1 medicines should not be judged by the scale alone. In a small SURMOUNT-1 DXA substudy of tirzepatide, most lost weight was fat mass, but some was lean mass. Lean mass is not the same as skeletal muscle alone. Protein planning, progressive resistance training and practical monitoring are practical safeguards for strength and function while losing weight.
A lower weight is not always the same as a better body.
When people ask about Ozempic, Wegovy or Mounjaro and the scale goes down, the useful question is simple: what was actually lost? Fat, muscle, or both?
EU indication boundary. Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with BMI at least 30, or BMI at least 27 to less than 30 with at least one weight-related comorbidity, and in adolescents from 12 years under product criteria. Mounjaro is indicated for type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above under product criteria, and for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with BMI at least 30, or BMI at least 27 to less than 30 with at least one weight-related comorbid condition. This article discusses body-composition planning around medically supervised weight management, not a claim that every named brand has the same EU indication.
This distinction matters because Élan is not trying to create lighter patients for a few months. We are trying to help people maintain the result with strength, function and better long-term habits.
The risk during fast weight loss
When calories are low and protein and training are not planned carefully, the body can lose lean tissue alongside fat.
We should be careful with exact percentages. Different studies measure body composition differently, and not every claim online is well supported. The practical message is still clear: without a specific plan, a meaningful part of weight loss can include lean tissue, not only fat.
Lean mass is not the same as skeletal muscle. DXA and similar trial measurements group muscle with water, glycogen, organs and other non-fat tissue. A fall in lean mass can still matter, but it should not be reported as if every kilogram were muscle.
For a patient, too much loss of strength or lean tissue can mean feeling weaker, recovering less well and having less capacity for the physical activity that supports long-term weight maintenance. Risk deserves particular attention in older adults, people with low baseline strength and people whose food intake has fallen sharply.
Why muscle matters
Muscle is not only about appearance or physical performance.
It matters for daily function: getting up from a chair, managing stairs, carrying shopping, keeping up with children or grandchildren. People using weight-management treatment are often already working on improving their health broadly. Maintaining physical capacity is part of that work.
Muscle also matters for metabolic health. It plays a role in glucose handling and energy use. Preserving it during weight loss is not a cosmetic goal. It is a health goal.
What a muscle-preserving plan includes
Protein. Protein is a practical support for preserving lean tissue during weight loss, but the evidence is not specific to every GLP-1 or GIP/GLP-1 medicine. The exact target should be individual, especially in kidney disease or other medical conditions. Because reduced appetite can make protein intake lower than expected, protein usually needs deliberate planning.
Resistance training. Walking is good for health. Progressive strength work adds a different signal: lifting, bodyweight work and resistance bands ask the body to keep using muscle during a deficit. The programme does not need to be extreme. It needs to be consistent and safe for the person doing it.
Monitoring more than weight. Body composition can matter more than weight alone, but it does not require expensive testing for every patient. Waist trend, strength, symptoms, nutrition review and simple physical performance checks are often practical first-line tools. Body-composition testing can help when available and interpreted correctly.
Not under-eating as a badge of honour. Very low food intake may speed short-term weight loss, but it can increase the risk of lean tissue loss and makes sustainable activity harder. The goal is a deficit that the body can manage, not a deficit that exhausts it.
Safety boundary. Routine dose, nutrition and training questions belong in a planned medical review. Seek urgent medical help the same day, or call 112 in Estonia, for persistent vomiting or inability to keep fluids down, dehydration, fainting, severe weakness, severe or persistent abdominal pain, chest symptoms, suicidal or self-harm thoughts, or possible hypoglycaemia if you use insulin or a sulfonylurea. If you are pregnant, planning pregnancy, breastfeeding or unsure about contraception, discuss this before starting, continuing, stopping or changing GLP-1 or GIP/GLP-1 treatment. Current EU product information says semaglutide should be stopped at least 2 months before a planned pregnancy and tirzepatide at least 1 month before a planned pregnancy.
In a DXA substudy of SURMOUNT-1, Look M et al. (Diabetes, Obesity and Metabolism, 2025; n=160) found that about 75% of weight lost with tirzepatide was fat mass and about 25% was lean mass. A similar fat to lean split was seen in the placebo group, so this pattern is not unique to the medicine. This was a small substudy, and lean mass was not the same as skeletal muscle. It supports monitoring, not alarmist claims.
Preserve the result, not only the number.
At Élan Clinic, body composition is part of weight-management planning. A body-composition and maintenance consultation can help you review protein, training, symptoms and monitoring options, then decide what practical next steps fit your situation.
Book a body-composition consultationQuestions patients ask
Is lean mass the same as skeletal muscle?
No. DXA and similar trial measurements group muscle with water, glycogen, organs and other non-fat tissue. A fall in lean mass can still matter, but it should not be reported as if every kilogram were muscle.
What can support strength during weight loss?
Protein planning, progressive resistance training and monitoring beyond scale weight are practical parts of a muscle-preserving plan. The exact approach should be individual, especially with kidney disease or other medical conditions.
When do symptoms need urgent help?
Seek urgent medical help the same day, or call 112 in Estonia, for persistent vomiting or inability to keep fluids down, dehydration, fainting, severe weakness, severe or persistent abdominal pain, chest symptoms, suicidal or self-harm thoughts, or possible hypoglycaemia if you use insulin or a sulfonylurea.
Sources and label information
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002. Randomised trial, n=1,961. PMID: 33567185. DOI: 10.1056/NEJMoa2032183. Funded by Novo Nordisk.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. Randomised trial, n=2,539. PMID: 35658024. DOI: 10.1056/NEJMoa2206038. Supported by Eli Lilly.
- Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. DXA substudy, n=160. PMID: 39996356. DOI: 10.1111/dom.16275. Includes Eli Lilly employee or shareholder disclosures and other industry conflict disclosures.
- Verreijen AM et al. A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial. American Journal of Clinical Nutrition. 2015;101(2):279-286. Randomised trial, n=80. PMID: 25646324. DOI: 10.3945/ajcn.114.090290.
- Phillips SM, Van Loon LJC. Dietary protein for athletes: from requirements to optimum adaptation. Journal of Sports Sciences. 2011;29 Suppl 1:S29-S38. Expert review. PMID: 22150425. DOI: 10.1080/02640414.2011.619204. Used here as indirect physiology support, not as GLP-1 outcome evidence.
- EMA Ozempic product information, EMA Wegovy product information and EMA Mounjaro product information. Used for EU indication, pregnancy, breastfeeding, contraception and safety-boundary wording.